Attorney Docket No. 23138-S Serial No.: 09/134,419

## Appendix 1

Amendments to pending claims: mark-up copy (37 C.F.R. 51.121(c) (ii)).

Please amend claim 1 as follows:

1. (Four times amended) A method for treating a nerverelated vision disorder or treating memory impairment in a mammal
in need thereof, which comprises administering to said mammal an
effective amount of a nitrogen-containing heterocyclic compound
having two or more heteroatoms,

wherein said compound has an N-linked substituent selected from the group consisting of -C(W)-C(Y)-

wherein W and Y are independently selected from the group consisting of O, S,  $CH_2$ , and  $H_2$ , wherein said compound is additionally substituted with a ester or amide substituent attached to the heterocyclic ring, and

wherein the nerve-related vision disorder is selected from the group consisting of the following:

visual impairments;

orbital disorders;

disorders of the lacrimal apparatus;

disorders of the eyelids;

Attorney Docket No. 23138-S Serial No.: 09/134,419

disorders of the conjunctiva;
disorders of the cornea;
cataract;
disorders of the uveal tract;
disorders of the retina;
disorders of the optic nerve or visual pathways;
free radical induced eye disorders and diseases;
immunologically-mediated eye disorders and diseases;
nerve-related physical injury affecting vision; and
nerve-related symptoms and complications of eye
disease, nerve-related symptoms and complications of eye
disorders, and nerve-related symptoms and complications
of physical injury affecting vision;

provided that said memory impairment is not a neurological disorder relating to neurodegeneration selected from the group consisting of Alzheimer's Disease and Parkinson's Disease.